2020 In Review: Despite Pandemic, The US FDA Issued Just 20% Fewer Drug GMP Warning Letters
2021 warning letter rate could decline further
The US FDA managed to issue 94 drug GMP warning letters last year despite the pandemic, with fewer expected for 2021. Top issue areas included lack of sterility assurance, nitrosamine impurities, poor data integrity and basic GMP failures.
You may also be interested in...
Import alert and warning letter came after Ningbo, China, over-the-counter skin care products firm failed to share requested testing records.
Look for alternative approaches like sample testing, remote records review and reliance on trusted host nation authorities to fill many inspection gaps – except for OAI re-inspections. Meanwhile, post-emergency planning begins.
New import alert category and border testing required after reduced standards put dangerous sanitizers into hands of US consumers.